Other languages Regencell Bioscience Holdings Limited

Equities

RGC

KYG7487R1002

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-10 pm EDT			5-day change	1st Jan Change
4.373 ^USD	-7.08%		-4.72%	-58.35%

2023	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI
2023	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-27
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-06-15
Regencell Bioscience Holdings Limited Promotes Yat-Pui Au from Senior Vice President to Chief Business Officer	23-02-28
Regencell Bioscience Holdings Limited Announces the Resignation of Yi-Chung Chao as Chief Medical Officer, with Effect from December 28, 2022	22-12-22
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-10-31
Regencell Bioscience Holdings Limited Announces its Standardized Formulae Shows Reduce ADHD and ASD Symptoms in Interim Results of its Second Efficacy Trial	22-09-12
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-06-02
Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period	22-05-18
La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...	22-02-17
La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...	22-02-17
Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen	22-02-17
Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días	22-02-17
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19 Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial	22-02-16
Regencell Bioscience : Forms Joint Venture to Offer COVID-19 Treatment to Select Asia Pacific Countries	21-09-02
Update: Regencell Bioscience Raises $24.9 Million from IPO -- Shares More Than Triple Amid Heavy Trading Volume	21-08-20
Regencell Bioscience : Says IPO Raised $24.9 Million	21-08-20
Regencell Bioscience Holdings Limited : anuncia oferta pública inicial en torno a los u$s 21.900 millones	21-07-16
Regencell Bioscience Holdings Limited : kondigt prijs aan van initiële openbare aanbieding van ongeveer $ 21,9 miljoen	21-07-16
Regencell Bioscience Holdings Limited : gibt Preis von rund 21,9 Millionen US-Dollar für seinen Börsengang bekannt	21-07-16
Regencell Bioscience Holdings Limited : annuncia il prezzo della sua offerta pubblica iniziale pari a circa 21,9 milioni di dollari	21-07-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Regencell Bioscience Holdings Limited

Equities

RGC

KYG7487R1002

Other languages

Filters